The Drug Repurposing Hub: a next-generation drug library and information resource.
作者信息
Corsello Steven M, Bittker Joshua A, Liu Zihan, Gould Joshua, McCarren Patrick, Hirschman Jodi E, Johnston Stephen E, Vrcic Anita, Wong Bang, Khan Mariya, Asiedu Jacob, Narayan Rajiv, Mader Christopher C, Subramanian Aravind, Golub Todd R
机构信息
Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
出版信息
Nat Med. 2017 Apr 7;23(4):405-408. doi: 10.1038/nm.4306.
Abstract
摘要
相似文献
1
The Drug Repurposing Hub: a next-generation drug library and information resource.
Nat Med. 2017 Apr 7;23(4):405-408. doi: 10.1038/nm.4306.
2
DrugR+: A comprehensive relational database for drug repurposing, combination therapy, and replacement therapy.
Comput Biol Med. 2019 Jun;109:254-262. doi: 10.1016/j.compbiomed.2019.05.006. Epub 2019 May 8.
3
Drug databases and their contributions to drug repurposing.
Genomics. 2020 Mar;112(2):1087-1095. doi: 10.1016/j.ygeno.2019.06.021. Epub 2019 Jun 18.
4
DrugMap Central: an on-line query and visualization tool to facilitate drug repositioning studies.
Bioinformatics. 2013 Jul 15;29(14):1834-6. doi: 10.1093/bioinformatics/btt279. Epub 2013 May 15.
5
Expanding the scope of drug repurposing in pediatrics: the Children's Pharmacy Collaborative.
Drug Discov Today. 2014 Nov;19(11):1696-1698. doi: 10.1016/j.drudis.2014.08.003. Epub 2014 Aug 19.
6
Web-based drug repurposing tools: a survey.
Brief Bioinform. 2019 Jan 18;20(1):299-316. doi: 10.1093/bib/bbx125.
7
DrugSig: A resource for computational drug repositioning utilizing gene expression signatures.
PLoS One. 2017 May 31;12(5):e0177743. doi: 10.1371/journal.pone.0177743. eCollection 2017.
8
PROMISCUOUS 2.0: a resource for drug-repositioning.
Nucleic Acids Res. 2021 Jan 8;49(D1):D1373-D1380. doi: 10.1093/nar/gkaa1061.
9
A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case.
BMC Syst Biol. 2015;9 Suppl 4(Suppl 4):S2. doi: 10.1186/1752-0509-9-S4-S2. Epub 2015 Jun 11.
10
Embracing the Landscape of Therapeutics.
Cell. 2020 Apr 2;181(1):1-3. doi: 10.1016/j.cell.2020.03.025.
引用本文的文献
1
Prioritizing FDA approved therapeutics for treating sepsis phenotypes: A network modeling approach based on neutrophil proteomics.
Front Immunol. 2025 Aug 14;16:1646141. doi: 10.3389/fimmu.2025.1646141. eCollection 2025.
2
Computational insights and experimental breakthroughs in identifying next-generation acetylcholinesterase inhibitors.
Sci Rep. 2025 Aug 29;15(1):31901. doi: 10.1038/s41598-025-17733-4.
3
Exploring the Impact of Bioactive Compounds Found in Extra Virgin Olive Oil on NRF2 Modulation in Alzheimer's Disease.
Antioxidants (Basel). 2025 Aug 2;14(8):952. doi: 10.3390/antiox14080952.
4
Off-label use of treprostinil in adult patients in clinical cases.
World J Clin Cases. 2025 Aug 16;13(23):107279. doi: 10.12998/wjcc.v13.i23.107279.
5
Modeling the genomic architecture of adiposity and anthropometrics across the lifespan.
Nat Commun. 2025 Aug 13;16(1):7494. doi: 10.1038/s41467-025-62730-w.
6
Ligand supplementation restores the cancer therapy efficacy of the antirheumatic drug auranofin from serum inactivation.
Nat Commun. 2025 Aug 9;16(1):7347. doi: 10.1038/s41467-025-62634-9.
7
Tricyclic Isatin Derivatives as Anti-Inflammatory Compounds with High Kinase Binding Affinity.
Molecules. 2025 Jul 10;30(14):2914. doi: 10.3390/molecules30142914.
8
Perturbation response scanning of drug-target networks: Drug repurposing for multiple sclerosis.
J Pharm Anal. 2025 Jun;15(6):101295. doi: 10.1016/j.jpha.2025.101295. Epub 2025 Apr 9.
9
Refate identifies chemical compounds to target trans-regulatory networks for cellular conversion.
bioRxiv. 2025 Jul 12:2025.07.09.664003. doi: 10.1101/2025.07.09.664003.
10
Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors.
Sci Adv. 2025 Jul 18;11(29):eadw5228. doi: 10.1126/sciadv.adw5228. Epub 2025 Jul 16.
本文引用的文献
1
Can you teach old drugs new tricks?
Nature. 2016 Jun 16;534(7607):314-6. doi: 10.1038/534314a.
2
High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines.
Nat Biotechnol. 2016 Apr;34(4):419-23. doi: 10.1038/nbt.3460. Epub 2016 Feb 29.
3
InChI, the IUPAC International Chemical Identifier.
J Cheminform. 2015 May 30;7:23. doi: 10.1186/s13321-015-0068-4. eCollection 2015.
4
Clinical development success rates for investigational drugs.
Nat Biotechnol. 2014 Jan;32(1):40-51. doi: 10.1038/nbt.2786.
5
Discovery and saturation analysis of cancer genes across 21 tumour types.
Nature. 2014 Jan 23;505(7484):495-501. doi: 10.1038/nature12912. Epub 2014 Jan 5.
6
Therapeutic target database update 2014: a resource for targeted therapeutics.
Nucleic Acids Res. 2014 Jan;42(Database issue):D1118-23. doi: 10.1093/nar/gkt1129. Epub 2013 Nov 21.
7
DrugBank 4.0: shedding new light on drug metabolism.
Nucleic Acids Res. 2014 Jan;42(Database issue):D1091-7. doi: 10.1093/nar/gkt1068. Epub 2013 Nov 6.
8
The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics.
Sci Transl Med. 2011 Apr 27;3(80):80ps16. doi: 10.1126/scitranslmed.3001862.
9
Stability through the ages: the GSK experience.
J Biomol Screen. 2009 Jun;14(5):547-56. doi: 10.1177/1087057109335327. Epub 2009 May 21.
10
Thalidomide for treatment of multiple myeloma: 10 years later.
Blood. 2008 Apr 15;111(8):3968-77. doi: 10.1182/blood-2007-10-117457. Epub 2008 Feb 1.
Zotero 插件